Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | voltage-gated potassium channel | 0.0108 | 0.0147 | 0.1028 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0108 | 0.0147 | 0.1145 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0372 | 0.1281 | 1 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0108 | 0.0147 | 0.1145 |
Loa Loa (eye worm) | hypothetical protein | 0.0323 | 0.107 | 0.107 |
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.0372 | 0.1281 | 1 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0407 | 0.1428 | 1 |
Loa Loa (eye worm) | inward rectifying k channel family protein 1 | 0.2404 | 1 | 1 |
Echinococcus granulosus | voltage gated potassium channel | 0.0108 | 0.0147 | 0.1145 |
Loa Loa (eye worm) | hypothetical protein | 0.2404 | 1 | 1 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0372 | 0.1281 | 1 |
Brugia malayi | Voltage-gated potassium channel, EAG (KCNH1)-related. C. elegans egl-2 ortholog | 0.0108 | 0.0147 | 0.1145 |
Loa Loa (eye worm) | hypothetical protein | 0.2404 | 1 | 1 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0348 | 0.1176 | 1 |
Toxoplasma gondii | hypothetical protein | 0.2404 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0108 | 0.0147 | 0.0147 |
Echinococcus multilocularis | voltage gated potassium channel | 0.0108 | 0.0147 | 0.1145 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0348 | 0.1176 | 1 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.0372 | 0.1281 | 0.1281 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0407 | 0.1428 | 1 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0108 | 0.0147 | 0.1028 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
BWLmax (functional) | < 0 % | Maximum rate of body weight loss after peroral administration of 11.9 mg/kg of compound in mice; <0 indicates no body weight loss | ChEMBL. | 15149677 |
BWLmax (functional) | < 0 % | Maximum rate of body weight loss after peroral administration of 7.9 mg/kg of compound in mice; <0 indicates no body weight loss | ChEMBL. | 15149677 |
BWLmax (functional) | < 0 % | Maximum rate of body weight loss after intravenous administration of 7.9 mg/kg of compound in mice; <0 indicates no weight loss | ChEMBL. | 15149677 |
BWLmax (functional) | < 0 % | Maximum rate of body weight loss after peroral administration of 11.9 mg/kg of compound in mice; <0 indicates no body weight loss | ChEMBL. | 15149677 |
BWLmax (functional) | < 0 % | Maximum rate of body weight loss after peroral administration of 7.9 mg/kg of compound in mice; <0 indicates no body weight loss | ChEMBL. | 15149677 |
BWLmax (functional) | < 0 % | Maximum rate of body weight loss after intravenous administration of 7.9 mg/kg of compound in mice; <0 indicates no weight loss | ChEMBL. | 15149677 |
BWLmax (functional) | = 1 % | Maximum rate of body weight loss after intravenous administration of 11.9 mg/kg of compound in mice | ChEMBL. | 15149677 |
BWLmax (functional) | = 1 % | Maximum rate of body weight loss after intravenous administration of 11.9 mg/kg of compound in mice | ChEMBL. | 15149677 |
BWLmax (functional) | = 8.6 % | Maximum rate of body weight loss after intravenous administration of 17.8 mg/kg of compound in mice | ChEMBL. | 15149677 |
BWLmax (functional) | = 8.6 % | Maximum rate of body weight loss after intravenous administration of 17.8 mg/kg of compound in mice | ChEMBL. | 15149677 |
BWLmax (functional) | = 8.8 % | Maximum rate of body weight loss after peroral administration of 17.8 mg/kg of compound in mice | ChEMBL. | 15149677 |
BWLmax (functional) | = 8.8 % | Maximum rate of body weight loss after peroral administration of 17.8 mg/kg of compound in mice | ChEMBL. | 15149677 |
BWLmax (functional) | = 13.1 % | Maximum rate of body weight loss after peroral administration of 26.7 mg/kg of compound in mice | ChEMBL. | 15149677 |
BWLmax (functional) | = 13.1 % | Maximum rate of body weight loss after peroral administration of 26.7 mg/kg of compound in mice | ChEMBL. | 15149677 |
ED50 (functional) | = 17.8 mg kg-1 | Effective dose of perorally administered compound against B16 melanoma BL6 cells implanted into mice; range is 7.9-17.8 | ChEMBL. | 15149677 |
ED50 (functional) | = 17.8 mg kg-1 | Effective dose of intravenously administered compound against B16 melanoma BL6 cells implanted into mice; range is 7.9-17.8 | ChEMBL. | 15149677 |
ED50 (functional) | = 17.8 mg kg-1 | Effective dose of perorally administered compound against B16 melanoma BL6 cells implanted into mice; range is 7.9-17.8 | ChEMBL. | 15149677 |
ED50 (functional) | = 17.8 mg kg-1 | Effective dose of intravenously administered compound against B16 melanoma BL6 cells implanted into mice; range is 7.9-17.8 | ChEMBL. | 15149677 |
GI50 (functional) | = 0.38 ng ml-1 | Concentration required to inhibit human PC-6 cell line growth by 50% at 72 h continuous exposure | ChEMBL. | 15149677 |
GI50 (functional) | = 0.38 ng ml-1 | Concentration required to inhibit human PC-6 cell line growth by 50% at 72 h continuous exposure | ChEMBL. | 15149677 |
GI50 (functional) | = 0.41 ng ml-1 | Concentration required to inhibit mouse P388 cell line growth by 50% at 72 h continuous exposure | ChEMBL. | 15149677 |
GI50 (functional) | = 0.41 ng ml-1 | Concentration required to inhibit mouse P388 cell line growth by 50% at 72 h continuous exposure | ChEMBL. | 15149677 |
GI50 (functional) | = 0.74 ng ml-1 | Concentration required to inhibit human PC-12 cell line growth by 50% at 72 h continuous exposure | ChEMBL. | 15149677 |
GI50 (functional) | = 4.04 ng ml-1 | Concentration required to inhibit human PC-6/VCR29-9 cell line growth by 50% at 72 hr exposure | ChEMBL. | 15149677 |
GI50 (functional) | = 4.04 ng ml-1 | Concentration required to inhibit human PC-6/VCR29-9 cell line growth by 50% at 72 hr exposure | ChEMBL. | 15149677 |
GI50 (functional) | = 54.2 ng ml-1 | Concentration required to inhibit human PC-6/VP1-1 cell line growth by 50% at 72 hr exposure | ChEMBL. | 15149677 |
GI50 (functional) | = 54.2 ng ml-1 | Concentration required to inhibit human PC-6/VP1-1 cell line growth by 50% at 72 hr exposure | ChEMBL. | 15149677 |
IR (functional) | = 72.8 % | Antitumour activity of 7.9 mg/kg of perorally administered compound against Bl6 melanoma BL6 cells implanted into mice, value reported is percent compared to control | ChEMBL. | 15149677 |
IR (functional) | = 72.8 % | Antitumour activity of 7.9 mg/kg of perorally administered compound against Bl6 melanoma BL6 cells implanted into mice, value reported is percent compared to control | ChEMBL. | 15149677 |
IR (functional) | = 82.3 % | Antitumour activity of 7.9 mg/kg of intravenously administered compound against Bl6 melanoma BL6 cells implanted into mice, value reported is percent compared to control | ChEMBL. | 15149677 |
IR (functional) | = 82.30000000000001 % | Antitumour activity of 7.9 mg/kg of intravenously administered compound against Bl6 melanoma BL6 cells implanted into mice, value reported is percent compared to control | ChEMBL. | 15149677 |
IR (functional) | = 88.8 % | Antitumour activity of 11.9 mg/kg of perorally administered compound against Bl6 melanoma BL6 cells implanted into mice, value reported is percent compared to control | ChEMBL. | 15149677 |
IR (functional) | = 88.80000000000004 % | Antitumour activity of 11.9 mg/kg of perorally administered compound against Bl6 melanoma BL6 cells implanted into mice, value reported is percent compared to control | ChEMBL. | 15149677 |
IR (functional) | = 95 % | Antitumour activity of 11.9 mg/kg of intravenously administered compound against Bl6 melanoma BL6 cells implanted into mice, value reported is percent compared to control | ChEMBL. | 15149677 |
IR (functional) | = 95 % | Antitumour activity of 11.9 mg/kg of intravenously administered compound against Bl6 melanoma BL6 cells implanted into mice, value reported is percent compared to control | ChEMBL. | 15149677 |
IR (functional) | = 97 % | Antitumour activity of 17.8 mg/kg of perorally administered compound against Bl6 melanoma BL6 cells implanted into mice, value reported is percent compared to control | ChEMBL. | 15149677 |
IR (functional) | = 97 % | Antitumour activity of 17.8 mg/kg of perorally administered compound against Bl6 melanoma BL6 cells implanted into mice, value reported is percent compared to control | ChEMBL. | 15149677 |
IR (functional) | = 97.5 % | Antitumour activity of 26.7 mg/kg of perorally administered compound against Bl6 melanoma BL6 cells implanted into mice, value reported is percent compared to control | ChEMBL. | 15149677 |
IR (functional) | = 97.5 % | Antitumour activity of 26.7 mg/kg of perorally administered compound against Bl6 melanoma BL6 cells implanted into mice, value reported is percent compared to control | ChEMBL. | 15149677 |
IR (functional) | = 97.7 % | Antitumour activity of 17.8 mg/kg of intravenously administered compound against Bl6 melanoma BL6 cells implanted into mice, value reported is percent compared to control | ChEMBL. | 15149677 |
IR (functional) | = 97.70000000000002 % | Antitumour activity of 17.8 mg/kg of intravenously administered compound against Bl6 melanoma BL6 cells implanted into mice, value reported is percent compared to control | ChEMBL. | 15149677 |
Mortality (functional) | = 0 | Number of mice died at 17.8 mg/kg of peroral dose among the total 6 mice tested | ChEMBL. | 15149677 |
Mortality (functional) | = 0 | Number of mice died at 11.9 mg/kg of peroral dose, among the total 6 mice tested | ChEMBL. | 15149677 |
Mortality (functional) | = 0 | Number of mice died at 7.9 mg/kg of peroral dose of compound among the total 6 mice tested | ChEMBL. | 15149677 |
Mortality (functional) | = 0 | Number of mice died at 17.8 mg/kg of intravenous dose among the total 6 mice tested | ChEMBL. | 15149677 |
Mortality (functional) | = 0 | Number of mice died at 11.9 mg/kg of intravenous dose, among the total 6 mice tested | ChEMBL. | 15149677 |
Mortality (functional) | = 0 | Number of mice died at 7.9 mg/kg of intravenous dose of compound among the total 6 mice tested | ChEMBL. | 15149677 |
Mortality (functional) | = 1 | Number of mice died at 26.7 mg/kg of peroral dose of compound among the total 6 mice tested | ChEMBL. | 15149677 |
Mortality (functional) | = 6 | Number of mice died at 26.7 mg/kg of intravenous dose of compound among the total 6 mice tested | ChEMBL. | 15149677 |
Remaining rate (functional) | = 84.8 % | Remaining rate after 5 min of incubation with human liver microsomes | ChEMBL. | 15149677 |
Remaining rate (functional) | = 84.8 % | Remaining rate after 5 min of incubation with human liver microsomes | ChEMBL. | 15149677 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.